^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    APR-1051

    i
    Other names: APR-1051, ATRN-1051, ATRN-W1051
    Company:
    Aprea
    Drug class:
    WEE1 inhibitor
    Related drugs:
    7ms
    APR-1051-001: Study of APR-1051 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=79, Recruiting, Aprea Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    APR-1051
    10ms
    Study of APR-1051 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=79, Not yet recruiting, Aprea Therapeutics
    New P1 trial
    |
    APR-1051
    almost2years
    ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment (AACR 2023)
    Importantly, ATRN-W1051 exhibits low off-target inhibition of the PLK family of kinases (PLK1, PLK2 and PLK3), which are substantially inhibited by the leading WEE1i in the clinic (AZD1775 and ZN-c3)1. These preclinical data suggest that ATRN-W1051 may be a potential therapeutic candidate for CCNE1-overexpressing HGSOC. Together, ATRN-119 and ATRN-W1051 provide promising alternative DNA replication checkpoint inhibitors for the treatment of a variety of cancers.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • PLK1 (Polo Like Kinase 1) • PLK2 (Polo Like Kinase 2)
    |
    CCNE1 amplification • CCNE1 overexpression
    |
    adavosertib (AZD1775) • azenosertib (ZN-c3) • APR-1051 • ATRN-119